Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577002 | 1.00 | NR1H2 (0.38) | NR1H2CTSKCA1CA2BTK | |
| SCHEMBL29072038 | 1.00 | NR1H2 (0.38) | NR1H2CTSKCA1CA2BTK | |
| SCHEMBL3575423 | 1.00 | NR1H2 (0.38) | NR1H2CTSKCA1CA2BTK | |
| SCHEMBL7804290 | 0.89 | NR1H2 (0.51) | NR1H2CTSKCA1CA2HSD11B1 | |
| SCHEMBL19695872 | 0.89 | NR1H2 (0.51) | NR1H2CTSKCA1CA2HSD11B1 | |
| SCHEMBL3834063 | 0.87 | CTSK (0.37) | CTSKCA1CA2BTKNFKB1 | |
| SCHEMBL3830675 | 0.87 | CTSK (0.37) | CTSKCA1CA2BTKNFKB1 | |
| SCHEMBL3832353 | 0.87 | CTSK (0.37) | CTSKCA1CA2BTKNFKB1 | |
| SCHEMBL29057864 | 0.87 | CTSK (0.37) | CTSKCA1CA2BTKNFKB1 | |
| SCHEMBL20722443 | 0.86 | CTSK (0.36) | CTSKCA1CA2BTKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116744929-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1626973-B1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE IS AN EFFECTIVE ANALGESIC AGENT | ABBOTT LAB (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1771451-B1 | (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBOTT LAB (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090203664-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090198067-A1 | (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
| US-7538226-B2 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050261348-A1 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040242641-A1 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | disclosed |
| US-20040242644-A1 | (IS-5S)-3-(5,6-dichloro-3-pyridinyl-)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | NR1H2 94/4885CTSK 2068/4885CA1 1477/4885 |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | DHPS, HCN2, DCPS | NR1H2 4685/4885CTSK 4358/4885CA1 867/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | NR1H2 1220/4885CTSK 4478/4885CA1 518/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | NR1H2 1240/4885CTSK 4545/4885CA1 438/4885 |
| US-20090203664-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | NR1H2 468/4885CTSK 3619/4885CA1 2058/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | NR1H2 1220/4885CTSK 4478/4885CA1 518/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | NR1H2 1240/4885CTSK 4545/4885CA1 438/4885 |
| US-20090198067-A1 | (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate | DHPS, HCN2, DCPS | NR1H2 4685/4885CTSK 4358/4885CA1 867/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | NR1H2 148/4885CTSK 2721/4885CA1 933/4885 |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | NR1H2 468/4885CTSK 3619/4885CA1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.